Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

PUMA BIOTECHNOLOGY, INC.

(PBYI)
  Report
Delayed Nasdaq  -  04:00 2022-12-02 pm EST
4.450 USD   -2.41%
11/11Puma Biotechnology to Pay $16 Million to Settle Defamation Lawsuit
MT
11/10Puma Biotechnology, Inc. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
11/03Puma Biotech : Q3 Earnings Snapshot
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Puma Biotech in Exclusive License Deal With Takeda

09/20/2022 | 04:52pm EST

By Stephen Nakrosis


Puma Biotechnology Inc. on Tuesday said it entered an exclusive license agreement with Takeda for the rights to alisertib, an inhibitor of aurora kinase A.

The deal will see Puma assume sole responsibility for the global development and commercialization of alisertib. Puma will pay Takeda an upfront license fee of $7 million, and Takeda is eligible to receive up to $287.3 million in milestone payments, the companies said.

Alisertib has been tested in clinical trials in patients with metastatic cancers including breast cancer and small cell lung cancer, as well as head and neck cancer and ovarian cancer, among others. Puma said it plans to initially focus on developing alisertib to treat patients with certain types of breast cancer and small cell lung cancer.


Write to Stephen Nakrosis at stephen.nakrosis@wsj.com


(END) Dow Jones Newswires

09-20-22 1651ET

Stocks mentioned in the article
ChangeLast1st jan.
PUMA BIOTECHNOLOGY, INC. -2.41% 4.45 Delayed Quote.46.38%
PUMA SE 0.24% 50.32 Delayed Quote.-53.19%
TAKEDA PHARMACEUTICAL COMPANY LIMITED -1.64% 3967 Delayed Quote.26.46%
All news about PUMA BIOTECHNOLOGY, INC.
11/11Puma Biotechnology to Pay $16 Million to Settle Defamation Lawsuit
MT
11/10Puma Biotechnology, Inc. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
11/03Puma Biotech : Q3 Earnings Snapshot
AQ
11/03Puma Biotechnology, Inc. Reports Earnings Results for the Third Quarter and Nine Months..
CI
11/03Transcript : Puma Biotechnology, Inc., Q3 2022 Earnings Call, Nov 03, 2022
CI
11/03Earnings Flash (PBYI) PUMA BIOTECHNOLOGY Posts Q3 EPS $0.05
MT
11/03Earnings Flash (PBYI) PUMA BIOTECHNOLOGY Reports Q3 Revenue $57.1M
MT
11/03Puma Biotechnology Reports Third Quarter 2022 Financial Results
BU
11/03Puma Biotechnology, Inc. Revises Earnings Guidance for the Full Year 2022
CI
11/02Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
BU
More news
Analyst Recommendations on PUMA BIOTECHNOLOGY, INC.
More recommendations
Financials (USD)
Sales 2022 220 M - -
Net income 2022 8,30 M - -
Net Debt 2022 - - -
P/E ratio 2022 25,5x
Yield 2022 -
Capitalization 203 M 203 M -
Capi. / Sales 2022 0,92x
Capi. / Sales 2023 0,87x
Nbr of Employees 196
Free-Float 86,1%
Chart PUMA BIOTECHNOLOGY, INC.
Duration : Period :
Puma Biotechnology, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PUMA BIOTECHNOLOGY, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 5
Last Close Price 4,45 $
Average target price 5,40 $
Spread / Average Target 21,3%
EPS Revisions
Managers and Directors
Alan H. Auerbach Founder
Maximo F. Nougues Chief Financial & Accounting Officer
Alvin Wong Senior VP-Clinical Science & Pharmacology
Jay M. Moyes Lead Independent Director
Troy E. Wilson Independent Director
Sector and Competitors
1st jan.Capi. (M$)
PUMA BIOTECHNOLOGY, INC.46.38%203
MODERNA, INC.-28.20%70 055
IQVIA HOLDINGS INC.-22.83%40 441
LONZA GROUP AG-33.82%39 802
ALNYLAM PHARMACEUTICALS, INC.38.22%28 838
SEAGEN INC.-20.82%22 727